Dear All,
>
> We've been consulted about a 23/12 old patient at the kids hospital in
> Perth who has developed disseminated non TB mycobacterium after Campath
> therapy for refractory Langerhan's Cell Histiocytosis (Histopath have
> assured us that the diagnosis is correct although there have been
> reports of LCH mimicing IFNgR deficiency which is known to respond to
> IFNg therapy).
>
> They've asked us about IFN g therapy as an option in this patient who
> has developed relapsed NTM involving the skin despite clarithromycin,
> rifabutin and ciprofloxacin. We are looking for a biomarker to prove IFN
> g pathway deficiency before embarking on this. Steve Holland from NIH
> has suggested doing CD119 (IFNgR1) on peripheral blood as an initial
> screen. We've found the Addenbroke's Hospital in the UK will examine the
> IL-12/IFNg/IFNgR pathway for us but we're wanting to know if anyone in
> Australia is doing this or has experience?
>
> Regards,
>
> Dr. Ben McGettigan
> Immunology Advanced Trainee
> Dept of Clinical Immunology
> Princess Margaret Hospital
> GPO Box D184 Perth WA 6840
> Ph
> Fax
